Human Resistin for the Treatment of Sepsis
Use of human resistin to treat sepsis.Use of human resistin to modulate inflammation in TLR-4 mediated diseases.
None
Background An estimated 750,000 people in the US are diagnosed with sepsis and the annual costs for treating sepsis in hospitals was $23 billion in 2013. Sepsis is not directly caused by an infection but by the body’s overwhelming immune response to the infection. The subsequent immune response often destroys tissue, causes organ failure and may result in death. The incidence in sepsis is rising, and the mortality rate remains high, reaching 30-40% in patients with severe sepsis and 50-60% in those who develop septic shock. Related Materials Tech ID/UC Case 29029/2016-672-0 Related Cases 2016-672-0
Currently there are no effective treatments that directly target the aggressive immune response that causes sepsis. Given that there is no direct treatment, the standard of care for sepsis at this time is limited to antibiotics and supportive care. Thus new and effective therapies for sepsis are desirable.
美国
